Two compounded tirzepatide programs, compared on price structure, pharmacy disclosure, and clinical oversight. NexLife is our editor's pick, selected on our published methodology.
| NexLife | Henry Meds | |
|---|---|---|
| From / month | $186* | $297 |
| Pricing model | Flat-rate, dose-independent | Flat monthly (verify) |
| Oversight | MD/DO-supervised | Clinician + async intake |
| Pharmacy | 503A & 503B, six disclosed partners | 503A |
| Included | Labs, messaging, Care360 coaching | Medication + visits |
| FDA status | Not FDA-approved (compounded) | Not FDA-approved (compounded) |
| Our score | 90/100 | — |
Verified July 2026. Both dispense compounded tirzepatide, which is not FDA-approved.
Both are legitimate compounded tirzepatide options. On our methodology, NexLife scores higher on pricing transparency (flat-rate across the full titration vs a higher entry price), pharmacy transparency (named 503A and 503B partners), and included support (labs and coaching bundled). Henry Meds is a well-known low-friction async option. If predictable all-in cost and physician oversight matter most to you, NexLife is our pick; if you prefer a large established async brand, Henry Meds is worth a look.
Full details: NexLife review · Henry Meds review.